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Background-—The relationship between late stent malapposition (LSM) and adverse cardiovascular events is controversial. Studies
are needed to evaluate long-term (>5 years) clinical outcomes of LSM detected by optical coherence tomography (OCT) after drug-
eluting stent implantation.
Methods and Results-—We investigated long-term clinical outcomes of OCT-detected LSM in 351 patients who received drug-
eluting stents and were examined by both poststent and follow-up OCT (17560 days after drug-eluting stent implantation) from
January 2009 to December 2011. LSM was observed in 99 patients (28%). We evaluated the cumulative rate of composite events
(cardiovascular death, target-vessel–related myocardial infarction, target-vessel revascularization, and stent thrombosis). During
80.124.5 months of follow-up, very late stent thrombosis did not occur in any patients with LSM. The cumulative 8-year rate of
composite events was 7.3% in patients with LSM and 10.5% in patients without LSM (P=0.822, log-rank test). We further divided
patients into the following 4 groups: patients with both late-persistent and late-acquired stent malapposition (n=23), patients with
late-persistent stent malapposition alone (n=45), patients with late-acquired stent malapposition alone (n=31), and patients
without LSM (n=252). The cumulative 8-year rates of composite events were similar among these 4 groups (0%, 9.6%, 9.7%, and
10.5%, respectively; P=0.468 by log-rank test).
Conclusions-—During long-term follow-up (>5 years), very late stent thrombosis did not occur in patients with OCT-detected LSM.
The rates of adverse clinical events were similar between patients with LSM versus those without LSM. Presence of OCT-detected
LSM was not associated with unfavorable clinical outcomes. ( J Am Heart Assoc.2019;8:e011817. DOI: 10.1161/JAHA.118.
011817.)
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Stent malapposition refers to the lack of contact betweenstent struts and the vessel wall.1 This phenomenon can be
detected by intracoronary imaging devices such as intravascu-
lar ultrasound (IVUS) and optical coherence tomography (OCT);
however, the clinical implications of IVUS- and OCT-detected
late stent malapposition (LSM) are still under debate.1
Compared with IVUS, OCT can detect stent malapposition with
greater accuracy because of its higher resolution.1,2 Theoret-
ically, a coronary thrombus could form around the stent
malapposition because of strut exposure and local ﬂow
disturbances,3 potentially serving as a substrate for (very) late
stent thrombosis. We previously reported that LSM was
frequently detected by OCT, but the clinical outcomes of
patients with LSM treated with drug-eluting stents (DESs) were
favorable over >2 years of follow-up.4 Studies are lacking
regarding longer term (>5 years) clinical outcomes of OCT-
detected LSM; therefore, in this study, we evaluated the longer
term clinical outcomes of OCT-detected LSM in these patients.4
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Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population
Using the OCT registry database of Severance Cardiovascu-
lar Hospital, we identiﬁed patients who underwent DES
implantation for de novo coronary lesions from January 2009
to December 2011, as well as poststent and follow-up OCT.4
OCT examination was performed at the discretion of
operators. Exclusion criteria were as follows: (1) DES
implanted to treat left main coronary disease, (2) overlap-
ping DESs in the lesion, (3) clinical follow-up after DES
implantation <1 year, (4) follow-up OCT performed >1 year
after DES implantation, and (5) poor-quality OCT image.4
Ultimately, 351 patients with 356 lesions were included in
this study.4 Figure 1 shows the ﬂow diagram for patient
selection. The DESs were chosen by operators at the time of
implantation and included sirolimus-eluting stents (Cypher;
Cordis), zotarolimus-eluting stents (Resolute or Integrity;
Medtronic), everolimus-eluting stents (Xience V; Abbott
Vascular), and biolimus A9–eluting stents (Nobori [Terumo
Corp] or Biomatrix [Biosensors International]). The DESs
were implanted using conventional techniques.5 Unfraction-
ated heparin was administered as an initial bolus of 100 IU/
kg, with additional boluses administered during the proce-
dure to achieve an activated clotting time of 250 to
Figure 1. Flow diagram for patient selection. DES indicates drug-eluting stent; OCT, optical coherence
tomography.
Clinical Perspective
What Is New?
• The relationship between late stent malapposition noted on
routine optical coherence tomography imaging after drug-
eluting stent implantation and adverse cardiovascular
events is still controversial.
• During long-term follow-up (>5 years), the rates of adverse
clinical events were similar between patients with and
without late stent malapposition.
What Are the Clinical Implications?
• The presence of late stent malapposition on follow-up
optical coherence tomography was not associated with
adverse cardiac events and does not need to be corrected.
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300 seconds. Dual antiplatelet therapy (aspirin and clopido-
grel) was provided to each patient until the follow-up OCT
was performed.4 Maintenance or discontinuation of dual
antiplatelet therapy after the follow-up OCT was at the
discretion of treating physicians. The study protocol was
approved by the institutional review board of our hospital,
and written informed consent was obtained from each
patient.
OCT Imaging and Analyses
We used 2 OCT systems in this study (M2 and C7-XR imaging
systems; LightLab Imaging, St. Jude Medical).6 All OCT images
were analyzed at a core laboratory (Cardiovascular Research
Center, Seoul, Korea) by analysts who were blinded to patient
and procedural information.4 Cross-sectional OCT images were
analyzed at 1-mm intervals. A malapposed strut was deﬁned as
Figure 2. Classiﬁcation of acute and late stent malapposition lesions based on poststent and follow-up
optical coherence tomography (OCT) ﬁndings. Modiﬁed from Im et al4 with permission from Wolters Kluwer
Health, Inc.
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a strut that was detached from the vessel wall as follows:
Cypher, ≥160 lm; Resolute or Integrity, ≥110 lm; Xience V,
≥100 lm; Nobori or Biomatrix, ≥130 lm.7 A coronary stent
malapposition detected immediately after DES implantation is
classiﬁed as acute stent malapposition, whereas one that is
detected later (during follow-up OCT) is classiﬁed as LSM.4
LSM can be further classiﬁed as late-persistent or late-acquired
stent malapposition. A late-persistent stent malapposition is an
acute stent malapposition that remains present at the follow-
up OCT. A late-acquired stent malapposition is a newly
developed stent malapposition that is identiﬁed on follow-up
OCT despite complete stent apposition on immediate post-
stent OCT.4 If malapposed struts were detected by poststent
OCT (ie, acute stent malapposition), each cross-section of the
poststent OCT image was matched with cross-sections of the
follow-up OCT image as accurately as possible based on the
distance from ﬁduciary landmarks (eg, stent edges, side
branches, or calciﬁcation).4,8 The lesions were then classiﬁed
as resolved acute stent malapposition lesions with or without
late-acquired stent malapposition or as late-persistent stent
malapposition lesions with or without late-acquired stent
malapposition4 (Figure 2). We then divided the patients into
the following 2 groups: patients with LSM (subgroups 1, 2, 4,
and 5 in Figure 2) and patients without LSM (subgroups 3 and
6 in Figure 2).
Clinical Follow-up
All patients were advised to maintain dual antiplatelet therapy
(aspirin and clopidogrel) for ≥6 months after DES implanta-
tion.4 During the follow-up period, most patients had a regular
follow-up visit at an outpatient clinic. We investigated clinical
events that were possibly related to LSM by reviewing medical
records at our institute until the date of the last ofﬁce visit.
These events included cardiovascular death, target-lesion–
and target vessel–related nonfatal myocardial infarction,
target-lesion and target-vessel revascularization, and stent
thrombosis. These clinical events were deﬁned according to
the recommendations of the Academic Research Consor-
tium.9 The event rates of each group were compared.
Statistical Analyses
Categorical variables are presented as number (percentage)
and were compared using v2 or Fisher exact tests. Contin-
uous variables are presented as meanSD and were
compared using Student t tests. Cumulative rates of com-
posite clinical events (cardiovascular death, target-vessel–
related myocardial infarction, target-vessel revascularization,
and stent thrombosis) were estimated with the Kaplan–Meier
method and compared among the groups with the log-rank
test. We estimated hazard ratios with 95% CIs for the
Figure 3. Incidences of acute and late stent malapposition detected on poststent and follow-up optical
coherence tomography (OCT). Three subgroups represent late-acquired stent malapposition lesions
(subgroups 2, 4, and 5). Modiﬁed from Im et al4 with permission from Wolters Kluwer Health, Inc.
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association of LSM with the composite events (cardiovascular
death, target-vessel–related myocardial infarction, target
vessel revascularization, and stent thrombosis) by Cox
regression analysis, adjusted for baseline clinical and proce-
dural variables. Variables with P<0.05 from univariate anal-
yses were included in the analysis. Statistical analyses were
performed using SPSS (v25.0; IBM Corp). P<0.05 was
considered signiﬁcant.
Results
The mean follow-up duration after DES implantation was
80.124.5 months, and follow-up OCT was performed on
average 17560 days after DES implantation.4 Even though
LSM was identiﬁed at follow-up OCT, no interventional
procedure was performed for the lesions with LSM. Patients
were divided into the following groups based on acute, late-
persistent, or late-acquired stent malapposition detected by
poststent and follow-up OCT: patients with LSM (subgroups 1,
2, 4, and 5 in Figure 3; 99 patients with 99 lesions) versus
patients without LSM (subgroups 3 and 6 in Figure 3; 252
patients with 257 lesions). Baseline characteristics of the 2
groups are summarized in Table 1. Compared with patients
without LSM, those with LSM showed a higher rate of calciﬁed
lesions, larger reference vessel diameter, higher preinterven-
tion percentage diameter stenosis, and larger stent diameter.
We compared clinical events for these 2 groups and found
that the rates of individual and composite events were similar
(Table 2). No very late stent thrombosis occurred in either
group. Figure 4 shows the Kaplan–Meier curves for the
composite events of cardiovascular death, target-vessel–
related myocardial infarction, target-vessel revascularization,
and stent thrombosis. The cumulative 8-year rate of composite
events was 7.3% in patients with LSM and 10.5% in patients
without LSM (P=0.822 by log-rank test). We further divided
patients into the following 4 groups: late-persistent stent
malapposition alone (subgroup 1; 45 patients with 45 lesions),
both late-persistent and late-acquired stent malapposition
(subgroup 2; 23 patients with 23 lesions), late-acquired stent
malapposition alone (subgroups 4 and 5; 31 patients with 31
lesions), and no LSM (subgroups 3 and 6; 252 patients with 257
lesions). The cumulative 8-year rates of composite events were
also similar among these 4 groups (9.6%, 0%, 9.7%, and 10.5%,
respectively; P=0.468 by log-rank test; Figure 5).
Of all 351 enrolled patients, 269 patients (77%) were
treated with new-generation DESs and the other 82 patients
(23%) were treated with a ﬁrst-generation DES. The number of
patients with late-persistent stent malapposition was 31 (12%)
with new-generation DESs and 14 (17%) with ﬁrst-generation
DES (P=0.188). The number of patients with late-acquired
stent malapposition was 41 (15%) with new-generation DESs
and 13 (16%) with a ﬁrst-generation DES (P=0.893).
Table 1. Baseline Patient Characteristics
Patients With
Late Stent
Malapposition
(n=99)
Patients Without
Late Stent
Malapposition
(n=252) P Value
Clinical characteristics
Age, y 67.516.4 69.419.2 0.382
Male sex 66 (67) 174 (69) 0.720
Hypertension 59 (60) 152 (61) 0.997
Diabetes mellitus 29 (30) 75 (30) 0.985
Dyslipidemia 59 (60) 130 (52) 0.176
Current smoking 23 (24) 48 (19) 0.350
Clinical presentation
of acute coronary
syndrome
35 (35) 71 (28) 0.187
Procedural characteristics
Lesions, n 99 257
Lesion in left
anterior descending
artery
61 (62) 139 (54) 0.199
Type B2 or C lesion 43 (45) 113 (46) 0.887
Calcified lesion 27 (27) 32 (13) 0.001
Reference vessel
diameter, mm
3.090.47 2.930.40 0.020
Preintervention
minimal lumen
diameter, mm
0.960.57 1.060.44 0.263
Postintervention
minimal lumen
diameter, mm
2.770.37 2.700.40 0.301
Preintervention
diameter stenosis, %
6918 6414 0.046
Postintervention
diameter stenosis, %
139 118 0.125
Lesion length, mm 17.76.8 17.76.3 0.976
Stent diameter, mm 3.220.35 3.130.36 0.035
Stent length, mm 19.35.4 18.75.2 0.397
Types of DES
First-generation DES
Sirolimus-eluting stent 27 (27) 56 (22) 0.273
New-generation DES
Zotarolimus-eluting stent 29 (29) 91 (35) 0.274
Everolimus-eluting stent 4 (4) 26 (10) 0.064
Biolimus-eluting stent 39 (40) 84 (33) 0.233
Predilation 99 (100) 253 (98) 0.579
Postdilation 55 (56) 143 (56) 0.988
Maximum pressure
in the dilated vessel, atm
133 143 0.113
Data are shown as meanSD or n (%) except as noted. DES indicates drug-eluting stent.
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In all 99 patients with LSM, the cumulative 8-year rates of
composite events were compared for patients with late-
acquired stent malapposition (subgroups 2, 4, and 5) versus
those with late-persistent stent malapposition (subgroup 1;
Figure 6A), with malapposition distance ≥400 versus
<400 lm (Figure 6B), and with malapposition length ≥1 ver-
sus <1 mm (Figure 6C). None of these comparisons achieved
statistically signiﬁcant differences.
LSM on follow-up OCT and variables with P<0.05 from
univariate analyses were entered into the Cox regression model
to identify independent predictors of the composite events and
to calculate their adjusted hazard ratio (Table 3). LSMon follow-
up OCT was not the independent predictor of the composite
events (hazard ratio: 0.48; 95% CI, 0.13–1.79; P=0.273).
Discussion
During long-term follow-up after DES implantation
(80.124.5 months), the cumulative rates of composite events
did not differ signiﬁcantly for patients with versus without
OCT-detected LSM. To the best of our knowledge, this study is
unique in its long-term follow-up (>5 years) for evaluation of
clinical outcomes of OCT-detected LSM and its larger number of
patients.
Table 2. Clinical Events During Follow-up*
Patients With
Late Stent
Malapposition
(n=99)
Patients Without
Late Stent
Malapposition
(n=252) P Value†
Follow-up duration, mo 80.519.8 79.926.1 0.825
Duration of DAPT, mo 13.96.6 14.38.7 0.651
At least 12 mo
of DAPT
78 (79) 184 (73) 0.263
Cardiovascular death 0 (0) 1 (0.4, 0.4 to 1.2) 0.522
Target-lesion–related MI 0 (0) 2 (0.9, 0.3 to 2.1) 0.676
Target-vessel–related MI 0 (0) 2 (0.9, 0.3 to 2.1) 0.676
Target-lesion
revascularization
2 (2.1, 0.6 to 4.8) 13 (5.8, 2.7–8.9) 0.151
Target-vessel
revascularization
7 (7.3, 2.0–12.6) 20 (10.1, 5.4–14.8) 0.615
Stent thrombosis
(definite or probable)
0 (0) 0 (0) 
Composite of
cardiovascular death,
target-lesion–related
MI, target-lesion
revascularization,
and stent thrombosis
2 (2.1, 0.6 to 4.8) 14 (6.3, 3.0–9.6) 0.293
Composite of
cardiovascular death,
target-vessel–related
MI, target-vessel
revascularization,
and stent thrombosis
7 (7.3, 2.0–12.6) 21 (10.5, 5.8–15.2) 0.822
*Data are expressed as meanSD, n (%), or number of patients (cumulative 8-year rate
of event [%], 95% CI). DAPT indicates dual antiplatelet therapy; MI, myocardial infarction.
†By the log-rank test.
Figure 4. Cumulative 8-year rate of composite events (cardio-
vascular death, target-vessel–related myocardial infarction, tar-
get-vessel revascularization, and stent thrombosis), as estimated
by Kaplan–Meier curves (late stent malapposition vs no late stent
malapposition).
Figure 5. Cumulative 8-year rate of composite events (cardio-
vascular death, target-vessel–related myocardial infarction, tar-
get-vessel revascularization, and stent thrombosis), as estimated
by Kaplan–Meier curves (both late-persistent and late-acquired
stent malapposition vs late-persistent stent malapposition alone
vs late-acquired stent malapposition alone vs no late stent
malapposition).
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Most studies evaluating long-term clinical outcomes in
patients with LSM after DESwere performedwith IVUS. The use
of both poststent and follow-up IVUS evaluations can discrim-
inate late-acquired stent malapposition from late-persistent
stent malapposition. Hong et al reported favorable long-term
(3 years) clinical outcomes in 80 patients with late-acquired
stent malapposition among 532 DES-treated patients who
underwent both poststent and follow-up IVUS examina-
tions.10,11 Other studies have also reported favorable long-
term clinical outcomes in patients treated with a bare-metal
stent or DES who had late-acquired stent malapposition.12–14
However, a study of 195 DES-treated patients suggested that
late-acquired stent malapposition may have been a risk factor
for late DES thrombosis in 23 patients with late-acquired stent
malapposition.15 Furthermore, 5-year follow-up of 194 DES-
treated patients reported that LSM (late-acquired or late-
persistent) was associated with a higher rate of very late DES
thrombosis in 37 patients with LSM.16 Unfortunately, discrim-
ination between late-acquired and late-persistent stent malap-
position was not possible in that study because poststent IVUS
data were not available.16 Of note, patients in those previous
studies were treated with ﬁrst-generation DESs.10–16 Because
of these conﬂicting results, the relationship between IVUS-
detected LSM and adverse cardiovascular events remains
unclear.1,17
Stent malapposition can be more reliably detected by OCT
than by IVUS1; however, few studies evaluating long-term
clinical outcomes of patients with OCT-detected LSM have had
adequate sample sizes. The proportion of malapposed stent
struts detected by OCT (up to 50% of stents implanted) is higher
than the proportion detected by IVUS (15% of stents
implanted).1,18 We previously reported that LSMwas frequently
detected in 351 DES-treated patients who underwent both
poststent and follow-upOCT examination, but clinical outcomes
of the patients with LSM (late-acquired or late-persistent) were
favorable during the 2-year follow-up period.4 The population of
that study was the DES-treated patients who underwent routine
OCT imaging and had a follow-up observation of subsequent
adverse events in daily clinical practice. In the present study, we
evaluated these patients over a longer follow-up period and
found no signiﬁcant difference in rates of adverse events of
patients with versus without LSM. In contrast, 3 recent registry
studies of patients presenting with stent thrombosis consis-
tently identiﬁed stent malapposition as a frequent underlying
abnormality.1,19–21 Therefore, the European expert consensus
recently recommended that extensively malapposed struts
should be avoided following stent implantation and should be
corrected when anatomically feasible.1 However, the partici-
pants in those studies were highly selected patients who
suffered from rare stent thrombosis, not the general DES-
treated patients. In addition, stent malapposition was not the
only ﬁnding responsible for stent thrombosis. Other stent
abnormalities such as underexpansion or uncovered struts
were also identiﬁed in some patients with stent thrombosis and
stent malapposition.19–21 Considering the high frequency of
OCT-detected stentmalapposition in daily clinical practice,1,4,18
the number of patients with OCT-detected stent malapposition
Figure 6. Cumulative 8-year rate of composite events (cardiovascular death, target-vessel–related myocardial infarction, target-vessel
revascularization, and stent thrombosis), as estimated by Kaplan–Meier curves for patients with late-acquired vs late-persistent stent
malapposition (A), malapposition distance ≥400 vs <400 lm (B), and malapposition length ≥1 vs <1 mm (C).
Table 3. Independent Predictor of the Composite Events*
Hazard Ratio (95% CI) P Value†
Late stent malapposition 0.48 (0.13–1.79) 0.273
Calcified lesion 0.96 (0.25–3.69) 0.953
Reference vessel diameter 0.46 (0.08–2.61) 0.377
Preintervention diameter stenosis 1.03 (1.00–1.06) 0.078
Stent diameter 1.01 (0.12–8.33) 0.995
*Composite events are cardiovascular death, target-vessel–related myocardial infarction,
target-vessel revascularization, and stent thrombosis.
†By Cox regression analysis.
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who develop stent thrombosis may be very small.19–21 Conse-
quently, longer term (>5 years) follow-up studies are necessary
to better understand the relationship between adverse clinical
events and LSM detected by OCT in daily clinical practice, not in
selected patients who presented with stent thrombosis.
However, studies evaluating relationships between adverse
clinical events and OCT-detected LSM during longer term
(>5 years) follow-up were lacking. Some registry studies have
already reported that acute stent malapposition on poststent
OCT were not associated with worse outcomes.22,23 In the
present study, no very late stent thrombosis occurred in
patients with OCT-detected LSM during 80.519.8 months of
follow-up. According to our results, the simple presence of LSM
on follow-up OCT was not associated with adverse cardiac
events and did not need to be corrected. Even after the
discontinuation of dual antiplatelet therapy, hard end points
such as cardiovascular death, myocardial infarction, or stent
thrombosis had not occurred in patients with LSM.
The favorable clinical outcomes observed in the present
study may be explained as follows.4 First, although large-sized
stent malapposition has been associated with late stent
thrombosis, small-sized stent malapposition that was detected
by OCT may not have a clinically important effect.4,24 Second,
continuous neointimal healing during the follow-up period may
decrease stent malapposition.4,25,26 Third, most lesions (77%)
were implanted with a new-generation DES in this study.4
The current study has several limitations. First, our study has
potential selection bias because of its cross-sectional design
and relatively small number of patients. Of all patients
implanted with a DES, a small proportion were included and
analyzed in this study. They were stable patients who under-
went follow-up OCT without additional intervention. This might
have caused sampling bias. Second, patients treated with ﬁrst-
generation DESs were also included in the study, and this limits
the general application of our results to the current clinical ﬁeld.
Third, the rate of hard end points such as cardiovascular death,
myocardial infarction, and stent thrombosis was low, suggest-
ing the possibility of a low-risk population.
Conclusions
During 80.124.5 months of follow-up, very late stent
thrombosis did not occur in 351 patients with OCT-detected
LSM. The rates of adverse clinical events were similar for
patients with and those without LSM.
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